Included with registration, selections made during registration process (non-cme events).

INDUSTRY BREAKFAST SYMPOSIA

WEDNESDAY MORNING, March 13, 7:00am-8:00am (non-CME)

S1 – Waking up to Endotoxemic Septic Shock. What to You Need to be Ready?
Moderators: John Kellum and Debra Foster
Diagnosing ESS in the real world – Danielle Davison, George Washington University
Treating ESS in the real world – Javier Neyra, University of Alabama
Implementing PMX hemoadsorption at the bedside – Johann Chang, (Spectral), Tara Morgan-Gray, (Colorado Springs)

Sponsored by: Spectral Medical

INDUSTRY LUNCH SYMPOSIA

WEDNESDAY AFTERNOON, March 13, 12:30PM-2:00pm (non-CME)

I1 – Renal Replacement Therapy Choices: What are the links to long term outcomes?
Advancements in Acute Kidney Injury drive us to seek a deeper understanding of the choices we make
and their impact on long-term outcomes. Delve into discussions on renal replacement therapy
nomenclature, the intricacies of membrane technology and the critical examination of how modality
choice may impact long-term renal recovery. Join us as we decipher these complexities and uncover the
links that shape the future of Critical Care Nephrology.
Moderator: Dr. Ron Wald
Nomenclature: What’s in a name? Aren’t they all the same? – Dr. Thiago Reis
Membranes: What is the difference? What difference do they make? – Dr. Manish Kaushik
Modality and Renal Recovery: Is there a link? – Dr. Ron Wald
Sponsored by: Baxter

I2 – Introducing Quelimmune: New Approved Therapy for Pediatric AKI due to Sepsis
Despite advancements in kidney replacement therapy, little improvement in morbidity and mortality rates of acute kidney injury (AKI) or sepsis-associated AKI (SA-AKI) have occurred over the past few decades. Mortality rates in children with AKI and multi-organ failure requiring continuous kidney replacement therapy (CKRT) continues to remain at ~50%. Additionally, children who survive an AKI episode are at increased risk of chronic kidney disease (CKD). This program will explore the background and clinical data of the pediatric selective cytopheretic device which recently received FDA approval for a Humanitarian Device Exemption in pediatric AKI due to sepsis.
Moderator: Stuart Goldstein
Speakers: Ayse Akcan-Arikan, Rajit Basu, David Askenazi
Sponsored by: SeaStar Medical

THURSDAY AFTERNOON, March 14, 12:30pm-2:00pm (non-CME)

I3 – Optical Sensors with Truly Regional Citrate Anticoagulation: Rationale, Implementation, and Prospects
This symposium on Combining Optical Sensors with Truly Regional Citrate Anticoagulation; Rationale, Implementation, and Prospects, will briefly review the principles of Truly regional citrate anticoagulation (True-RCA), combining the use of optical sensors with a discussion of potential future directions. Afterward, join the panel for a roundtable discussion with audience Q&A. We look forward to a dynamic dialogue with you.
Moderator: David Thompson
Speaker: Balazs Szamosfalvi
Sponsored by: Fresenius

I4 – From Crisis to Control: Extracorporeal Pathogen Removal as a Core Strategy in the Treatment of Sepsis – An ExThera Medical Affairs Update
Critically ill patients with sepsis have limited therapy options. This symposium will discuss the ExThera’s latest investigations and data in pathogen adsorption through Extracorporeal Blood Purification.
Moderator: Lui Forni, MD
Presentation Title: New Developments & Clinical Application Pathways in Pathogen Extracorporeal Blood Purification (EBP) – Sanja Ilic, MD
Presentation Title: Pathogen Removal in the Post-Pandemic Era – Jonathan Chow, MD
Sponsored by: ExThera Medical